Human carcinogen exposure: Biomonitoring and risk assessment

1992 ◽  
Vol 30 (4) ◽  
pp. 341-342
Author(s):  
Rupert Purchase
Author(s):  
Sheldon Krimsky

This chapter explores the glaring scientific differences in the human health assessment of the popular herbicide glyphosate between European and American institutions. The International Agency for Research on Cancer (IARC) classified glyphosate as a probable human carcinogen, while the U.S. Environmental Protection Agency (EPA) concluded that glyphosate is not likely to be carcinogenic to humans. Both IARC's and the EPA's carcinogenic risk assessment processes are discussed. This work reveals uncertainties in the sciences of toxicology and epidemiology, as well as assumptions made in their applications for evaluating glyphosate. These uncertainties, along with the political context of chemical risk assessment, are at the root of the divergent findings on the carcinogenic risks of glyphosate.


2021 ◽  
Vol 9 (2) ◽  
pp. 77-80
Author(s):  
Umesh Dobariya ◽  
Narendra Chauhan ◽  
Himani Patel ◽  
Nidhi Pardeshi

The unexpected finding of presence of nitrosamine impurities, by USFDA and EMA in year 2018, in drugs such as Angiotensin-II Receptor Blockers (ARBs), Ranitidine, Nizatidine and Metformin, has triggered the need for a risk assessment strategy for evaluation and control of these probable human carcinogen - nitrosamine in pharmaceutical product that are at risk. This finding leads to voluntarily recall of products worldwide. The finding of nitrosamines in some types of drug products led FDA and other international regulators to conduct a detailed risk assessment of these impurities in APIs and drug products. Although nitrosamine impurities have been found in only some drug products, regulatory agencies recommended to extend risk analysis in other chemically synthesized APIs and drug products also.


2020 ◽  
Author(s):  
Federica Chiara ◽  
Stefano Indraccolo ◽  
Andrea Trevisan

Abstract In the past two decades, a ponderous epidemiological literature has causally linked tumor onset to environmental exposure to carcinogens. As consequence, risk assessment studies have been carried out with the aim to identify both predictive models of estimating cancer risks within exposed populations and establishing rules for minimizing hazard when handling carcinogenic compounds. The central assumption of these works is that neoplastic transformation is directly related to the mutational burden of the cell without providing further mechanistic clues to explain increased cancer onset after carcinogen exposure. Nevertheless, in the last few years, a growing number of studies have implemented the traditional models of cancer aetiology, proposing that neoplastic transformation is a complex process in which several parameters and crosstalk between tumor and microenvironmental cells must be taken into account and integrated with mutagenesis. In this conceptual framework, the current strategies of risk assessment that are solely based on the “mutator model” require an urgent update and revision to keep pace with advances in our understanding of cancer biology. We will approach this topic revising the most recent theories on the biological mechanisms involved in tumor formation in order to envision a roadmap leading to a future regulatory framework for a new, protective policy of risk assessment.


1994 ◽  
Vol 26 (1-2) ◽  
pp. 111-124 ◽  
Author(s):  
Paul L. Skipper ◽  
Xiaocong Peng ◽  
Carlton K. Soohoo ◽  
Steven R. Tannenbaum

1998 ◽  
Vol 62 (10) ◽  
pp. 756-761 ◽  
Author(s):  
CW Douglass
Keyword(s):  

2006 ◽  
Vol 175 (4S) ◽  
pp. 531-532
Author(s):  
Matthew R. Cooperberg ◽  
Stephen J. Freedland ◽  
David J. Pasta ◽  
Eric P. Elkin ◽  
Joseph C. Presti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document